Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016


  • Products Id :- GMDHC8455IDB
  • |
  • Pages: 192
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

- The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects

- The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Keratoconjunctivitis sicca (Dry Eye) Overview 9

Therapeutics Development 10

Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10

Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 11

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 12

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes 16

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 21

Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes 25

Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 26

AB2 Bio Ltd. 26

Allergan Plc 27

Ascendia Pharmaceuticals LLC 28

Chong Kun Dang Pharmaceutical Corp. 29

Digna Biotech, S.L. 30

Dompe Farmaceutici S.p.A. 31

HanAll Biopharma Co., Ltd. 32

Herantis Pharma Plc 33

Huons Co., Ltd. 34

InSite Vision Incorporated 35

Kala Pharmaceuticals, Inc. 36

Kissei Pharmaceutical Co., Ltd. 37

KPI Therapeutics, Inc. 38

Kukje Pharmaceutical Industry Co., Ltd. 39

Laboratoires Thea S.A. 40

Lee's Pharmaceutical Holdings Limited 41

Lipicard Technologies Limited 42

Merck & Co., Inc. 43

Mimetogen Pharmaceuticals Inc. 44

Mitotech S.A. 45

Nanomerics Ltd 46

Neuroptis Biotech 47

Novaliq GmbH 48

Ocular Therapeutix, Inc. 49

Oculis ehf 50

OncoNOx ApS 51

Otsuka Holdings Co., Ltd. 52

Parion Sciences, Inc. 53

Quorum Innovations LLC 54

RegeneRx Biopharmaceuticals, Inc. 55

Rigel Pharmaceuticals, Inc. 56

Samjin Pharmaceutical Co., Ltd. 57

Santen Pharmaceutical Co., Ltd. 58

Seikagaku Corporation 59

Sucampo Pharmaceuticals, Inc. 60

TearSolutions, LLC. 61

TopiVert Ltd 62

Xigen SA 63

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 64

Assessment by Monotherapy Products 64

Assessment by Target 65

Assessment by Mechanism of Action 69

Assessment by Route of Administration 73

Assessment by Molecule Type 75

Drug Profiles 77

AGN-223575 - Drug Profile 77

AGN-232411 - Drug Profile 78

Androgen Tears - Drug Profile 79

AVA-3486 - Drug Profile 80

AVX-012 - Drug Profile 81

BRM-421 - Drug Profile 82

cinhyaluronate sodium - Drug Profile 83

Cis-Urocanic Acid - Drug Profile 84

cyclosporine - Drug Profile 87

cyclosporine - Drug Profile 90

cyclosporine - Drug Profile 92

cyclosporine - Drug Profile 93

cyclosporine - Drug Profile 94

cyclosporine - Drug Profile 95

cyclosporine - Drug Profile 96

cyclosporine - Drug Profile 97

cyclosporine SR - Drug Profile 98

dexamethasone acetate SR - Drug Profile 99

diclofenac sodium - Drug Profile 104

diquafosol tetrasodium - Drug Profile 105

disitertide - Drug Profile 107

Drugs to Agonize FPR2 for Dry Eye - Drug Profile 109

Elate Ocular - Drug Profile 110

HL-036 - Drug Profile 111

HU-007 - Drug Profile 112

hyaluronate sodium - Drug Profile 113

ISV-101 - Drug Profile 114

K-089 - Drug Profile 115

KeraKlear - Drug Profile 116

KJ-14003 - Drug Profile 117

KL-7016 - Drug Profile 118

KPI-190 - Drug Profile 119

Lacripep - Drug Profile 120

LME-636 - Drug Profile 121

loteprednol etabonate - Drug Profile 122

LT-4002 - Drug Profile 125

LT-4003 - Drug Profile 126

NOP-3 - Drug Profile 127

NOP-5 - Drug Profile 128

Nov-03 - Drug Profile 129

OC-301 - Drug Profile 130

OX-1001 - Drug Profile 131

ozagrel - Drug Profile 132

P-321 - Drug Profile 133

plastoquinone decyl triphenylphosphonium bromide - Drug Profile 135

PPL-003 - Drug Profile 137

Qi-204 - Drug Profile 139

R-348 - Drug Profile 140

rebamipide - Drug Profile 142

Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 144

RGN-259 - Drug Profile 146

RP-101 - Drug Profile 153

RU-101 - Drug Profile 154

SA-001 - Drug Profile 156

SJP-002 - Drug Profile 157

Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile 158

ST-266 - Drug Profile 159

tadekinig alfa - Drug Profile 161

tavilermide hydrochloride - Drug Profile 162

TOP-1630 - Drug Profile 164

XG-104 - Drug Profile 165

ZK-003 - Drug Profile 166

zucapsaicin - Drug Profile 167

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 169

Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 175

Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 176

Featured News & Press Releases 176

Appendix 187

Methodology 187

Coverage 187

Secondary Research 187

Primary Research 187

Expert Panel Validation 187

Contact Us 187

Disclaimer 188

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016 14

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 68

Number of Products by Top 10 Targets, H2 2016 69

Number of Products by Stage and Top 10 Targets, H2 2016 69

Number of Products by Top 10 Mechanism of Actions, H2 2016 73

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 73

Number of Products by Top 10 Routes of Administration, H2 2016 77

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 77

Number of Products by Molecule Types, H2 2016 79

Number of Products by Stage and Molecule Types, H2 2016 79

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016 14

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Comparative Analysis by Unknown Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H2 2016 30

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2016 31

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016 32

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 33

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2016 34

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 35

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 36

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2016 37

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2016 38

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2016 39

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 40

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 41

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics, Inc., H2 2016 42

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 43

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea S.A., H2 2016 44

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 45

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2016 46

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2016 47

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016 48

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H2 2016 49

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2016 50

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2016 51

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2016 52

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H2 2016 53

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2016 54

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2016 55

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 56

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2016 57

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2016 58

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 59

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 60

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H2 2016 61

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 62

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2016 63

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 64

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H2 2016 65

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2016 66

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2016 67

Assessment by Monotherapy Products, H2 2016 68

Number of Products by Stage and Target, H2 2016 70

Number of Products by Stage and Mechanism of Action, H2 2016 74

Number of Products by Stage and Route of Administration, H2 2016 78

Number of Products by Stage and Molecule Type, H2 2016 80

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2016 173

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H2 2016 174

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H2 2016 175

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H2 2016 176

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H2 2016 177

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..5), H2 2016 178

Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2016 179

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB2 Bio Ltd.

Allergan Plc

Ascendia Pharmaceuticals LLC

Chong Kun Dang Pharmaceutical Corp.

Digna Biotech, S.L.

Dompe Farmaceutici S.p.A.

HanAll Biopharma Co., Ltd.

Herantis Pharma Plc

Huons Co., Ltd.

InSite Vision Incorporated

Kala Pharmaceuticals, Inc.

Kissei Pharmaceutical Co., Ltd.

KPI Therapeutics, Inc.

Kukje Pharmaceutical Industry Co., Ltd.

Laboratoires Thea S.A.

Lee's Pharmaceutical Holdings Limited

Lipicard Technologies Limited

Merck & Co., Inc.

Mimetogen Pharmaceuticals Inc.

Mitotech S.A.

Nanomerics Ltd

Neuroptis Biotech

Novaliq GmbH

Ocular Therapeutix, Inc.

Oculis ehf

OncoNOx ApS

Otsuka Holdings Co., Ltd.

Parion Sciences, Inc.

Quorum Innovations LLC

RegeneRx Biopharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

Samjin Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd.

Seikagaku Corporation

Sucampo Pharmaceuticals, Inc.

TearSolutions, LLC.

TopiVert Ltd

Xigen SA

Keratoconjunctivitis sicca (Dry Eye) Therapeutic Products under Development, Key Players in Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Keratoconjunctivitis sicca (Dry Eye) Pipeline Overview, Keratoconjunctivitis sicca (Dry Eye) Pipeline, Keratoconjunctivitis sicca (Dry Eye) Pipeline Assessment

select a license

Single User License
USD 2000 INR 128700
Site License
USD 4000 INR 257400
Corporate User License
USD 6000 INR 386100

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com